Investing.com - ResMed (NYSE: RMD) reported fourth quarter EPS of $2.08, in line with the analyst estimate of $2.08. Revenue for the quarter came in at $1.22B versus the consensus estimate of $1.22B.
ResMed's stock price closed at $214.56. It is down -1.12% in the last 3 months and down -3.42% in the last 12 months.
ResMed saw 9 positive EPS revisions and 0 negative EPS revisions in the last 90 days. See ResMed's stock price’s past reactions to earnings here.
According to InvestingPro, ResMed's Financial Health score is "great performance".
Check out ResMed's recent earnings performance, and ResMed's financials here.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar